Ronit Simantov

14.4k total citations · 4 hit papers
88 papers, 11.2k citations indexed

About

Ronit Simantov is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Ronit Simantov has authored 88 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Pulmonary and Respiratory Medicine, 36 papers in Molecular Biology and 26 papers in Oncology. Recurrent topics in Ronit Simantov's work include Renal cell carcinoma treatment (29 papers), Cancer Genomics and Diagnostics (14 papers) and Renal and related cancers (11 papers). Ronit Simantov is often cited by papers focused on Renal cell carcinoma treatment (29 papers), Cancer Genomics and Diagnostics (14 papers) and Renal and related cancers (11 papers). Ronit Simantov collaborates with scholars based in United States, Canada and United Kingdom. Ronit Simantov's co-authors include Brian Schwartz, Martin Gore, Tim Eisen, Walter M. Stadler, Apurva A. Desai, Ronald M. Bukowski, Bernard Escudier, Minghua Shan, Cezary Szczylik and Stéphane Oudard and has published in prestigious journals such as New England Journal of Medicine, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Ronit Simantov

87 papers receiving 10.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma

2007 3.8k citations Bernard Escudier, Tim Eisen et al. New England Journal of Medicine profile →
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer

2006 1.4k citations Scott M. Wilhelm, Christopher Carter et al. Nature Reviews Drug Discovery profile →
Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus

2003 1.1k citations Mary J. Roman, Beth‐Ann Shanker et al. New England Journal of Medicine profile →
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma

2006 794 citations Mark J. Ratain, Tim Eisen et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Ronit Simantov

Since Specialization

Citations

This map shows the geographic impact of Ronit Simantov's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ronit Simantov with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ronit Simantov more than expected).

Fields of papers citing papers by Ronit Simantov

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ronit Simantov. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ronit Simantov. The network helps show where Ronit Simantov may publish in the future.

Co-authorship network of co-authors of Ronit Simantov

This figure shows the co-authorship network connecting the top 25 collaborators of Ronit Simantov. A scholar is included among the top collaborators of Ronit Simantov based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ronit Simantov. Ronit Simantov is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Projected Impact of Omidubicel-onlv on Racial/Ethnic Disparities in Allogeneic Hematopoietic Cell Transplantation (Allo-HCT) Outcomes in Hematologic Malignancies 2024 ·Advances in Therapy ·Nandita Khera, (unknown), Yan Song, (unknown), (unknown), (unknown), Ronit Simantov, James Signorovitch, (unknown), Usama Gergis	1
2	The Impact of Age and Gender on Outcomes of Patients With Advanced Renal Cell Carcinoma Treated With Targeted Therapy 2020 ·Clinical Genitourinary Cancer ·(unknown), Xun Lin, Ronit Simantov, Ithaar Derweesh, Toni K. Choueiri, Rana R. McKay	9
3	The Clinical Presentation, Survival Outcomes, and Management of Patients With Renal Cell Carcinoma and Cardiac Metastasis Without Inferior Vena Cava Involvement: Results From a Pooled Clinical Trial Database and Systematic Review of Reported Cases 2017 ·Clinical Genitourinary Cancer ·(unknown), (unknown), Guillermo de Velasco, (unknown), Xun Lin, Craig Norton, Ronit Simantov, Javid J. Moslehi, Katherine M. Krajewski, Toni K. Choueiri, Rana R. McKay	13
4	Proton Pump Inhibitors and Survival Outcomes in Patients With Metastatic Renal Cell Carcinoma 2017 ·Clinical Genitourinary Cancer ·Aly‐Khan A. Lalani, Rana R. McKay, Xun Lin, Ronit Simantov, Marina D. Kaymakcalan, Toni K. Choueiri	38
5	Statins and survival outcomes in patients with metastatic renal cell carcinoma 2015 ·European Journal of Cancer ·Rana R. McKay, Xun Lin, Laurence Albigès, André P. Fay, Marina D. Kaymakcalan, (unknown), P. Peter Ghoroghchian, Rupal S. Bhatt, (unknown), Ronit Simantov, Toni K. Choueiri, Daniel Yick Chin Heng	40
6	Phase I Study of Intermittent Oral Dosing of the Insulin-like Growth Factor-1 and Insulin Receptors Inhibitor OSI-906 in Patients With Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Robin L. Jones, Edward S. Kim, Pilar Nava-Parada, Salma Alam, Faye M. Johnson, Andrew Stephens, Ronit Simantov, Srinivasu Poondru, (unknown), Scott M. Lippman, Stan B. Kaye, Craig P. Carden	77
7	A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors 2014 ·Clinical Cancer Research ·Igor Puzanov, Colin R. Lindsay, Laura W. Goff, Jeff Sosman, Jill Gilbert, Jordan Berlin, Srinivasu Poondru, Ronit Simantov, (unknown), Andrew Stephens, (unknown), T.R. Jeffry Evans	78
8	Comparison of central and intraesophageal factors between gastroesophageal reflux disease (GERD) patients and those with GERD-related noncardiac chest pain 2012 ·Diseases of the Esophagus ·Michael Shapiro, Ronit Simantov, (unknown), Marina Leitman, Alex Blatt, E Scapa, Efrat Broide	8
9	Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer 2010 ·Clinical Cancer Research ·April A. N. Rose, Andrée‐Anne Grosset, Zhifeng Dong, Caterina Russo, Patricia MacDonald, Nicholas Bertos, Yves St‐Pierre, Ronit Simantov, Michael Hallett, Morag Park, Louis Gaboury, Peter M. Siegel	157
10	GPNMB Expression in Uveal Melanomas: A Potential for Targeted Therapy 2009 ·Investigative Ophthalmology & Visual Science ·Bita Esmaeli, Michelle D. Williams, (unknown), Dan S. Gombos, Ronit Simantov	1
11	Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma breakdown → 2007 ·New England Journal of Medicine ·Bernard Escudier, Tim Eisen, Walter M. Stadler, Cezary Szczylik, Stéphane Oudard, Michael Siebels, Sylvie Négrier, Christine Chevreau, E Solska, Apurva A. Desai, Frédéric Rolland, Tomasz Demkow, Thomas E. Hutson, Martin Gore, Sara M. Freeman, Brian Schwartz, Minghua Shan, Ronit Simantov, Ronald M. Bukowski	3804
12	Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma breakdown → 2006 ·Journal of Clinical Oncology ·Mark J. Ratain, Tim Eisen, Walter M. Stadler, Keith T. Flaherty, Stan B. Kaye, Gary L. Rosner, Martin Gore, Apurva A. Desai, Amita Patnaik, Henry Q. Xiong, Eric K. Rowinsky, James L. Abbruzzese, Chenghua Xia, Ronit Simantov, Brian Schwartz, Peter J. O’Dwyer	794
13	Neprilysin Inhibits Angiogenesis via Proteolysis of Fibroblast Growth Factor-2 2006 ·Journal of Biological Chemistry ·Oscar B. Goodman, Maria Febbraio, Ronit Simantov, Rong Zheng, Ruoqian Shen, Roy L. Silverstein, David M. Nanus	41
14	Discovery and development of sorafenib: a multikinase inhibitor for treating cancer breakdown → 2006 ·Nature Reviews Drug Discovery ·Scott M. Wilhelm, Christopher Carter, Mark Lynch, Timothy B. Lowinger, Jacques Dumas, Roger A. Smith, Brian Schwartz, Ronit Simantov, Susan L. Kelley	1447
15	Annexin II regulates fibrin homeostasis and neoangiogenesis in vivo 2004 ·Journal of Clinical Investigation ·Ling Qi, Andrew T. Jacovina, Arunkumar B. Deora, Maria Febbraio, Ronit Simantov, Roy L. Silverstein, Barbara Hempstead, Willie Mark, Katherine A. Hajjar	318
16	Genomic absence of the gene encoding T cell receptor V_β7.2 is linked to the presence of autoantibodies in Sjögren's syndrome 2004 ·Arthritis & Rheumatism ·(unknown), (unknown), Westley H. Reeves, Frank C. Arnett, Antje Necker, Ronit Simantov, Robert Lyons, Minoru Satoh, David N. Posnett	8
17	Prevalence and Correlates of Accelerated Atherosclerosis in Systemic Lupus Erythematosus breakdown → 2003 ·New England Journal of Medicine ·Mary J. Roman, Beth‐Ann Shanker, Adrienne Davis, Michael D. Lockshin, Lisa R. Sammaritano, Ronit Simantov, Mary K. Crow, Joseph E. Schwartz, Stephen A. Paget, Richard B. Devereux, Jane E. Salmon	1053
18	High Affinity Binding of β2-Glycoprotein I to Human Endothelial Cells Is Mediated by Annexin II 2000 ·Journal of Biological Chemistry ·Keying Ma, Ronit Simantov, (unknown), Roy L. Silverstein, Katherine A. Hajjar, Keith R. McCrae	182
19	FACTOR V LEIDEN INCREASES THE RISK OF THROMBOSIS IN PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES 1996 ·Thrombosis Research ·Ronit Simantov, S K Lo, Jane E. Salmon, Lisa R. Sammaritano, Roy L. Silverstein	20
20	Effects of acute and chronic morphine treatment of calmodulin activity of rat brain. 1982 ·Molecular Pharmacology ·(unknown), (unknown), Ronit Simantov	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact